Global Non-Hematological Cancers Market to 2021 | Latest Research Report

Researchmoz added Most up-to-date research on "Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics" to its huge collection of research reports.

In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis, non-hematological cancers are thought to account for 94% of global cancer prevalence. The key cancer indications of this report, namely breast, colorectal, lung and prostate cancer, constitute approximately 51% of global cancer prevalence.

The risk of cancer increases greatly in patients over the age of 65. As populations are projected to increase, with aging and increasing incidence of obesity, the prevalence of cancer as a genetic disease is only anticipated to increase, thereby acting as a driver for revenue growth. Typically, chemotherapy has curative or palliative uses depending on whether the patient’s tumors are resectable or unresectable, respectively; however, use of chemotherapies is often reliant on performance status, which is lacking in many cancer patients.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=716914

There has been a shift towards developing targeted therapies, which by their nature have less toxicity associated with their use and as a result can be administered to greater numbers of cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.

Scope

Global revenues for the non-hematological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.86%, from $73 billion in 2014 to $141 billion in 2021

What is the generic penetration?
Which drugs will achieve blockbuster status?

Overall, there are 6,484 oncology products in the pipeline, which make it the largest therapy area pipeline

How does the composition of the pipeline compare with that of the existing market?
What mechanisms of action are most common for pipeline drugs?

18 of the top 20 pharmaceutical companies will market non-hematological cancer drugs in the forecast period

How is their revenue share of the non-hematological cancer market set to change?
What CAGR will these companies register in the forecast period?

Reasons to buy

This report will allow you to -

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis
Visualize the composition of the non-hematological cancer market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
Analyze the non-hematological cancer pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
Understand the growth in patient epidemiology and market revenues for the non-hematological cancer market globally and across the key players and product types
Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various non-hematological cancers
Identify commercial opportunities in the non-hematological cancer deals landscape by analyzing trends in licensing and co-development deals

Browse Detail Report With TOC @ http://www.researchmoz.us/global-nonhematological-cancers-market-to-2021-strong-growth-driven-by-increased-uptake-of-low-toxicity-targeted-treatments-and-versatile-biologics-report.html

Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6

2 Introduction 9
2.1 Therapy Area Introduction 9
2.2 Symptoms 10
2.3 Etiology and Pathophysiology 11
2.3.1 Etiology 11
2.3.2 Pathophysiology 12
2.3.3 Tumor Initiation 13
2.3.4 Enhanced Growth, Evasion of Apoptosis and Replicative Immortality 14
2.3.5 Tumor Metabolic Shift 17
2.3.6 Tumor Progression, Invasion and Metastasis 17
2.3.7 Evasion of the Immune Response 19
2.3.8 Cancer Stem Cells 20
2.4 Co-morbidities and Complications 20
2.5 Epidemiology Patterns - Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 21
2.5.1 Breast Cancer 22
2.5.2 Colorectal Cancer 22
2.5.3 Lung Cancer 23
2.5.4 Prostate Cancer 24
2.6 Treatment 25
2.6.1 Surgery and Radiation Therapy 26
2.6.2 Chemotherapy 27
2.6.3 Hormonal Therapies 29
2.6.4 Targeted Therapies 30

3 Key Marketed Products 32
3.1 Overview 32
3.2 Avastin (bevacizumab) 33
3.3 Herceptin (trastuzumab) 35
3.4 Alimta (pemetrexed) 37
3.5 Zytiga (abiraterone acetate) 38
3.6 Xtandi (enzalutamide) 39
3.7 Perjeta (pertuzumab) 40
3.8 Tarceva (erlotinib hydrochloride) 41
3.9 Yervoy (ipilimumab) 43
3.10 Conclusion 44

4 Pipeline Landscape Assessment 45
4.1 Overview 45
4.2 Pipeline Development Landscape 45
4.3 Molecular Targets in the Pipeline 49
4.4 Clinical Trials 52
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 53
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 56
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 60
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 64
4.4.5 Conclusion 68
4.5 Assessment of Key Pipeline Products 69
4.5.1 Neratinib - Puma Biotechnology 69
4.5.2 AZD-4736 - AstraZeneca 70
4.5.3 LY2835219 - Eli Lilly 71
4.5.4 LEE-011 - Novartis 72
4.5.5 JNJ-56021927 - Johnson & Johnson 73
4.5.6 Tremelimumab - AstraZeneca 74
4.5.7 Margetuximab - Macrogenics 75
4.5.8 Conclusion 76

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=716914

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us

This release was published on openPR.